Is There a Right or Wrong in the Debate Between Patients and Manufacturers to Release Drugs Through Compassionate Use?
source: pixabay.com

Is There a Right or Wrong in the Debate Between Patients and Manufacturers to Release Drugs Through Compassionate Use?

  Following several Patient Worthy articles on the subject earlier this year, Fierce Biotech recently published news that Biogen is preparing to release the Phase III VALOR trial drug, tofersen,…

Continue Reading Is There a Right or Wrong in the Debate Between Patients and Manufacturers to Release Drugs Through Compassionate Use?
New Hope for ALS and Friedreich’s Ataxia Patients Through Viral Vector Transports
mcmurryjulie / Pixabay

New Hope for ALS and Friedreich’s Ataxia Patients Through Viral Vector Transports

A recent announcement in Biospace by Capsida Biotherapeutics and CRISPR Therapeutics of their newly-formed partnership offers renewed hope for amyotrophic lateral sclerosis (ALS) and Friedreich’s Ataxia patients. The companies believe…

Continue Reading New Hope for ALS and Friedreich’s Ataxia Patients Through Viral Vector Transports
Masitinib Studies Suspended Over Ischemic Heart Disease Risk
https://pixabay.com/en/anatomy-human-heart-pulse-frequency-2328534/

Masitinib Studies Suspended Over Ischemic Heart Disease Risk

Altogether, AB Science has been evaluating a tyrosine kinase inhibitor, masitinib, for a variety of conditions including amyotrophic lateral sclerosis (ALS), COVID-19, and mastocytosis. But according to ALS News Today,…

Continue Reading Masitinib Studies Suspended Over Ischemic Heart Disease Risk